Overall survival of metastatic colorectal cancer in Lima: relationship with the KRAS gene mutational status

Descripción del Articulo

Objectives: the main goal for this study was to evaluate overall survival in mCRC patients with mutated vs. wild type KRAS gene (exon 2) status. Materials and methods: between January 2010 and December 2013, data from clinical records of mCRC patients from different hospitals in Lima, stating an ass...

Descripción completa

Detalles Bibliográficos
Autor: Aldecoa, Franklin
Formato: artículo
Fecha de Publicación:2020
Institución:Colegio Médico del Perú
Repositorio:Acta Médica Peruana
Lenguaje:español
OAI Identifier:oai:ojs.pkp.sfu.ca:article/868
Enlace del recurso:https://amp.cmp.org.pe/index.php/AMP/article/view/868
Nivel de acceso:acceso abierto
Materia:Cancer, colorectal
/genetics
Mutation
Exons
id REVCMP_832a69d923ac92b5f674b59609842803
oai_identifier_str oai:ojs.pkp.sfu.ca:article/868
network_acronym_str REVCMP
network_name_str Acta Médica Peruana
repository_id_str .
spelling Overall survival of metastatic colorectal cancer in Lima: relationship with the KRAS gene mutational statusSupervivencia global del cáncer colorrectal metastásico en Lima Metropolitana: relación con el estado mutacional del gen KRASAldecoa, FranklinCancer, colorectal/geneticsMutationExonsObjectives: the main goal for this study was to evaluate overall survival in mCRC patients with mutated vs. wild type KRAS gene (exon 2) status. Materials and methods: between January 2010 and December 2013, data from clinical records of mCRC patients from different hospitals in Lima, stating an assessment of the KRAS gene mutation status (exon 2), were analyzed. Kaplan-Meier survival estimates and Log-Rank or Breslow Test were used to compare the survival curves. Results: three-hundred and twenty cases were analyzed. There were 227 patients (70.93%) with wild type KRAS and 93 (29.07%) with mutated KRAS. The overall survival of mCRC patients and mutated KRAS was higher than that of patients with wild type KRAS (HR: 0.73; 95% CI: 0.55–0.98; P= 0.037). Conclusion: patients with mCRC and mutated KRAS who were studied in Lima have higher survival rates compared to wild type patients, being this different from what is found in the world literature.Objetivos: el objetivo principal del estudio fue evaluar la supervivencia global en pacientes con carcinoma colorrectal metastásico (CCRm) cuyos tumores tuvieran el gen KRAS mutado frente al no mutado. Materiales y métodos: se analizaron los datos de las historias clínicas de pacientes con CCRm (enero 2010 - diciembre 2013) de diferentes hospitales de Lima Metropolitana, cuyos tumores tuvieron evaluación del estado mutacional del exón 2, gen KRAS. Se usaron la curva de supervivencia de Kaplan-Meier y la prueba de long rank o Breslow para las comparaciones de las curvas de supervivencia. Resultados: de los 320 casos analizados, hubo 227 pacientes (70,93%) con KRAS no mutado y 93 (29,07%) con KRAS mutado. La supervivencia global de pacientes con CCRm y KRAS mutado fue mayor que los pacientes con KRAS no mutado (hazart ratio: 0,73; IC 95% 0,55 – 0,98; p=0,037). Conclusión: la población con CCRm y KRAS mutado estudiada en centros médicos de Lima Metropolitana tuvo una supervivencia mayor, comparada con la no mutada, comportamiento diferente a lo encontrado en la literatura mundial.Colegio Médico del Perú2020-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://amp.cmp.org.pe/index.php/AMP/article/view/86810.35663/amp.2020.372.868ACTA MEDICA PERUANA; Vol 37 No 2 (2020): April - JuneACTA MEDICA PERUANA; Vol. 37 Núm. 2 (2020): Abril - Junio1728-59171018-8800reponame:Acta Médica Peruanainstname:Colegio Médico del Perúinstacron:CMPspahttps://amp.cmp.org.pe/index.php/AMP/article/view/868/437Copyright (c) 2020 ACTA MEDICA PERUANAinfo:eu-repo/semantics/openAccessoai:ojs.pkp.sfu.ca:article/8682023-07-06T05:50:52Z
dc.title.none.fl_str_mv Overall survival of metastatic colorectal cancer in Lima: relationship with the KRAS gene mutational status
Supervivencia global del cáncer colorrectal metastásico en Lima Metropolitana: relación con el estado mutacional del gen KRAS
title Overall survival of metastatic colorectal cancer in Lima: relationship with the KRAS gene mutational status
spellingShingle Overall survival of metastatic colorectal cancer in Lima: relationship with the KRAS gene mutational status
Aldecoa, Franklin
Cancer, colorectal
/genetics
Mutation
Exons
title_short Overall survival of metastatic colorectal cancer in Lima: relationship with the KRAS gene mutational status
title_full Overall survival of metastatic colorectal cancer in Lima: relationship with the KRAS gene mutational status
title_fullStr Overall survival of metastatic colorectal cancer in Lima: relationship with the KRAS gene mutational status
title_full_unstemmed Overall survival of metastatic colorectal cancer in Lima: relationship with the KRAS gene mutational status
title_sort Overall survival of metastatic colorectal cancer in Lima: relationship with the KRAS gene mutational status
dc.creator.none.fl_str_mv Aldecoa, Franklin
author Aldecoa, Franklin
author_facet Aldecoa, Franklin
author_role author
dc.subject.none.fl_str_mv Cancer, colorectal
/genetics
Mutation
Exons
topic Cancer, colorectal
/genetics
Mutation
Exons
description Objectives: the main goal for this study was to evaluate overall survival in mCRC patients with mutated vs. wild type KRAS gene (exon 2) status. Materials and methods: between January 2010 and December 2013, data from clinical records of mCRC patients from different hospitals in Lima, stating an assessment of the KRAS gene mutation status (exon 2), were analyzed. Kaplan-Meier survival estimates and Log-Rank or Breslow Test were used to compare the survival curves. Results: three-hundred and twenty cases were analyzed. There were 227 patients (70.93%) with wild type KRAS and 93 (29.07%) with mutated KRAS. The overall survival of mCRC patients and mutated KRAS was higher than that of patients with wild type KRAS (HR: 0.73; 95% CI: 0.55–0.98; P= 0.037). Conclusion: patients with mCRC and mutated KRAS who were studied in Lima have higher survival rates compared to wild type patients, being this different from what is found in the world literature.
publishDate 2020
dc.date.none.fl_str_mv 2020-07-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/868
10.35663/amp.2020.372.868
url https://amp.cmp.org.pe/index.php/AMP/article/view/868
identifier_str_mv 10.35663/amp.2020.372.868
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/868/437
dc.rights.none.fl_str_mv Copyright (c) 2020 ACTA MEDICA PERUANA
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 ACTA MEDICA PERUANA
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Colegio Médico del Perú
publisher.none.fl_str_mv Colegio Médico del Perú
dc.source.none.fl_str_mv ACTA MEDICA PERUANA; Vol 37 No 2 (2020): April - June
ACTA MEDICA PERUANA; Vol. 37 Núm. 2 (2020): Abril - Junio
1728-5917
1018-8800
reponame:Acta Médica Peruana
instname:Colegio Médico del Perú
instacron:CMP
instname_str Colegio Médico del Perú
instacron_str CMP
institution CMP
reponame_str Acta Médica Peruana
collection Acta Médica Peruana
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1816075103017893888
score 13.889614
Overall survival of metastatic colorectal cancer in Lima: relationship with the KRAS gene mutational status
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).

Ejemplares Similares